Evotec in two chemistry deals

Psychiatric Genomics (Gaithersburg, Md.) and Evotec (FSE:EVT) partnered to develop small molecules to treat psychiatric diseases. Under the three-year deal, EVT will provide medicinal chemistry services to design compound libraries around chemical structures identified by Psychiatric Genomics' genome-based Multi-Parameter High Throughput Screen platform. EVT also will assist in lead generation and optimization, and also will provide ADMET profiling. The deal is EVT's third partnership with an Oxford Bioscience portfolio company. ...